Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease

References

• Pagliusi SR, Aguado TA. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23:569-78; PMID:15630792; http://dx.doi.org/10.1016/j.vaccine.2004.07.046
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. In: WHO Expert Committee on Biological Standardization. 57th Report Geneva 2006. Accessed Nov. 4, 2015, http://www.who.int/biologicals/vaccines/hpv/Annex_1_WHO_TRS_962-2.pdf?ua=1
   Google Scholar
• World Health Organization International Agency for Research on Cancer. Primary end-points for prophylactic HPV vaccine trials. IARC Working Group Report 2014; 7. Accessed June 30, 2015. Available at http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk7/Prophylactic_HPV_VaccineTrials.pdf
   Google Scholar
• Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013; 22:553-60; PMID:23549399; http://dx.doi.org/10.1158/1055-9965.EPI-12-1406
   PubMed Web of Science ®Google Scholar
• Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole C, Smith JS. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2013; 133:1271-85; PMID:22961444; http://dx.doi.org/10.1002/ijc.27828
   PubMed Web of Science ®Google Scholar
• Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168:123-37; PMID:18483125; http://dx.doi.org/10.1093/aje/kwn036
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40; PMID:2727467; http://dx.doi.org/10.1002/sim.4780080407
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004; 329:168-9; PMID:15258077; http://dx.doi.org/10.1136/bmj.329.7458.168
   PubMed Web of Science ®Google Scholar
• Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Abrahantes JC, Buyse M. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 2004 Sep; 60:724-8; PMID:15339295; http://dx.doi.org/10.1111/j.0006-341X.2004.00222.x
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3e3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641
   PubMed Web of Science ®Google Scholar
• World Health Organization International Agency for Research on Cancer. Primary end-points for prophylactic HPV vaccine trials. IRAC Working Group Report 2014; 7. Accessed June 30, 2015. Available at http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk7/Prophylactic_HPV_VaccineTrials.pdf.
   Google Scholar
• Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105:28-37; PMID:21629249; http://dx.doi.org/10.1038/bjc.2011.185
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• International patent numbers WO 2003/019143 A2, WO 2006/116276 A2, and WO 2006/116303 A2. Available at http://www.wipo.int/portal/en
   Google Scholar
• Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27; PMID:16394035; http://dx.doi.org/10.1097/01.AOG.0000192397.41191.fb
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Diagnostic tests. 1: sensitivity and specificity. BMJ 1994; 308:1552; PMID:8019315; http://dx.doi.org/10.1136/bmj.308.6943.1552
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994; 309:102; PMID:8038641; http://dx.doi.org/10.1136/bmj.309.6947.102
   PubMed Web of Science ®Google Scholar
• Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991; 44:763-70; PMID:1941027; http://dx.doi.org/10.1016/0895-4356(91)90128-V
   PubMed Web of Science ®Google Scholar